Our Causes & Efforts
Childhood brain tumors are complicated to diagnosis, treat and monitor. Through our fundraising efforts we can provide the funds necessary for a more precise protocol for each patient with a focus on the most common brain tumor Medulloblastoma. The areas of focus include:
Radiation therapy planning & treatment
Precision diagnosis (cellular & molecular pathology, genetics)
Hematology & oncology therapy protocols
Rehabilitation and nutrition
Family mentoring & support
100% of all proceeds will go directly toward research in these areas
Currently only 4% of National Institute of Health (NIH) funds are allocated to pediatric cancer. Of this 4% only 1% is directed to Pediatric Brain Tumor Research. In 2018, the Childhood Cancer STAR ACT was passed which benefits the pediatric cancer community. The passing of this act, however, is just the first step to getting Closer to the Cure and increasing the quality of life for survivors. Your funding is another step closer!
What is Medulloblastoma?
Medulloblastoma is the most prevalent type of childhood brain cancers. It is fast growing, but if caught in time, with aggressive treatment, can be treated.
Medulloblastoma tumors often originate in the cerebellum or the posterior fossa (back of the brain). Like other brain tumors, Medulloblastoma can spread to other locations in the brain and spinal cord.
Treatment consists of surgery through the back of the head to remove the tumor, followed by radiation to the brain & spine (if the child is old enough), and a cocktail of chemotherapy drugs over 6-15 months depending on the specific type of tumor.
Prognosis is highly varied but in aggregate viewed as favorable. Certain genetic and tumor location profiles can have poor or favorable prognosis, however these markers account for a minority of children diagnosed with Medulloblastoma today. Most kids are "in the middle", because we do not know enough about how the tumors work to classify them.
For children that do survive Medulloblastoma, they must constantly wrestle with the late-onset effects from the aggressive treatment regimen received. More research funding into the area of tumor classification will allow for less aggressive, more precision treatments. Surgery, radiation and chemotherapy each bring their own risks and complications as survivors grow up. These complications can include neurological deficits, hearing loss, growth & hormone imbalances, reduced fertility, and other cancers.
Medulloblastoma collaborative projects
past and present
2019 American Society of Clinical Oncology (ASCO) Young Investigator Award in medullo. Stingray Therapeutics is introducing an immune-therapy in medulloblastoma.
#cureMedullo is investing deeply and directing funds into this novel immune-therapy that the Director of #cureMedullo believes is ‘vastly differentiated from typical biotech investments’. READ DETAILS